The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Eudy, Rena J ^a   Sahasrabudhe, Vaishali ^a   Sweeney, Kevin ^a   Tugnait, Meera ^a   King Ahmad, Amanda ^a   Near, Kristen ^a   Loria, Paula ^a   Banker, Mary E ^a   Piotrowski, David W ^a   Boustany Kari, Carine M ^a,b  

^a PFIZER INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPLERENONE; HORMONE RECEPTOR BLOCKING AGENT; MINERALOCORTICOID RECEPTOR; PF 03882845; PLACEBO; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DRUG DERIVATIVE; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; IN VITRO STUDY; MALE; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; POTASSIUM URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RAT; RECEPTOR BLOCKING; SINGLE DRUG DOSE; SODIUM URINE LEVEL; VOLUNTEER; ANIMAL; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; METABOLISM; SPRAGUE DAWLEY RAT; TIME; TRANSLATIONAL RESEARCH; TUMOR CELL LINE; URINE;

ADULT; ALDOSTERONE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CELL LINE, TUMOR; HUMANS; MALE; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SODIUM; SPIRONOLACTONE; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 80054716865     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-180     Document Type: Article

References (44)

1. Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol Endocrinol Metab 1990, 258:E482-484.
2. Mehdi U, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650. 10.1681/ASN.2009070737, 2794224, 19926893.
3. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-543. 10.1161/HYPERTENSIONAHA.109.131110, 19635989.
4. Bailey M, Mullins J, Kenyon C. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium. Hypertension 2009, 54:890-896. 10.1161/HYPERTENSIONAHA.109.134973, 19635986.
5. Epple HJ, Amasheh A, Mankertz J, Goltz M, Schulzke JD, Fromm M. Early aldosterone effect in distal colon by transcriptional regulation of ENaC. Am J Physiol Gastrointest Liver Physiol 2000, 27:G718-724.
6. Lam EYM, Funder JW, Nikolic-Paterson DJ, Fuller PJ, Young MJ. Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats. Endocrinology 2006, 147:3623-3629. 10.1210/en.2005-1527, 16627578.
7. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology 2007, 12:261-266. 10.1111/j.1440-1797.2007.00796.x, 17498121.
8. Danda R, Habiba N, Rincon-Choles H, Bhandari B, Barnes J, Abboud H, Pergola P. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005, 38:2562-2571.
9. Brosius F, Alpersb C, Bottingerc E, Breyerd M, Coffmane T, Gurleye S, Harrisf R, Kakokig M, Kretzlera M, Leiterh E, et al. Mouse models of diabetic nephropathy: A midstream Analysis from the animal models of diabetic complications consortium. JASN 2009, 20:2503-2512.
10. Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR. Effect of eplerenone, enalapril and their combination treatmentment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009, 24:73-84.
11. Blasi E, Rocha R, Rudolph A, Blomme E, Polly M, McMahon E. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791-1800. 10.1046/j.1523-1755.2003.00929.x, 12675855.
12. Gasparo M, Joss U, Ramjoue H, Whitebread S, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650-656.
13. Kagawa C, RS Jacobs J. Mineralocorticoid effects of 9 alpha-fluorodeoxycorticosterone in adrenalectomized rats. Proc Soc Exp Biol Med 1960 May;104:60-2 1960, 104:60-66.
14. Brandish PE, Chen H, Szczerba P, Hershey JC. Development of a Simplified assa for determination of antimineralocorticoid activity of compounds dosed in rats. J Pharmacol Toxicol Methods 2008, (57):155-160.
15. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
16. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117-123. 10.1161/01.HYP.0000025146.19104.FE, 12154100.
17. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996, 28:269-275.
18. Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol Renal Physiol 1979, 236:F246-F251.
19. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001, 28:231-252. 10.1023/A:1011527125570, 11468939.
20. Beal SL. Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2002, 29:403-410. 10.1023/A:1020909324909, 12518711.
21. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger J-D, Rossier BC. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994, 367:463-467. 10.1038/367463a0, 8107805.
22. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, Aldrich G, Fejes-Toth G. Sgk is an aldosterone-induced kinase in the renal collecting duct - Effects on epithelial Na channels. J Biol Chem 1999, 274:16973-16978. 10.1074/jbc.274.24.16973, 10358046.
23. Chen S, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone GL, Verrey F, Pearce D. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:2514-2519. 10.1073/pnas.96.5.2514, 26816, 10051674.
24. Yonemura K, Yasuda H, Hishida A. Distinct responses of membranoproliferative glomerulonephritis- related proteinuria to spironolactone with and without angiotensin II blockade. Ann Intern Med 2003, 139:W-79-.
25. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving H-H. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836. 10.1111/j.1523-1755.2005.00756.x, 16316360.
26. Peti-Peterdi J, Warnock DG, Bell PD. Angiotensin II directly stimulates ENaC activity in the cortical dollecting duct via AT1 receptors. J Am Soc Nephrol 2002, 13:1131-1135. 10.1097/01.ASN.0000013292.78621.FD, 11960999.
27. Beutler KT, Masilamani S, Turban S, Nielsen J, Brooks HL, Ageloff S, Fenton RA, Packer RK, Knepper MA. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 2003, 41:1143-1150. 10.1161/01.HYP.0000066129.12106.E2, 12682079.
28. Frindt G, Burg M. Effect of vasopressin on sodium transport in renal cortical collecting tubules. Kidney Int 1972, 1:224-231. 10.1038/ki.1972.32, 4671214.
29. Ecelbarger CA, Kim G-H, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol 2000, 279:F46-53.
30. Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension 2001, 38:1143-1149. 10.1161/hy1001.092641, 11711512.
31. Bobulescu IA, Dwarakanath V, Zou L, Zhang J, Baum M, Moe OW. Glucocorticoids acutely increase cell surface Na+/H+ exchanger-3 (NHE3) by activation of NHE3 exocytosis. Am J Physiol Renal Physiol 2005, 289:F685-691. 10.1152/ajprenal.00447.2004, 2861571, 15942046.
32. Stanton BA. Regulation by adrenal corticosteroids of sodium and potassium transport in loop of Henle and distal tubule of rat kidney. J Clin Invest 1986, 78:1612-1620. 10.1172/JCI112754, 423933, 3023448.
33. Velazquez H, Bartiss A, Bernstein P, Ellison DH. Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules. Am J Physiol Renal Physiol 1996, 270:F211-219.
34. Gaeggeler H-P, Gonzalez-Rodriguez E, Jaeger NF, Loffing-Cueni D, Norregaard R, Loffing J, Horisberger J-D, Rossier BC. Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J Am Soc Nephrol 2005, 16:878-891. 10.1681/ASN.2004121110, 15743993.
35. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na and K transport. Am J Physiol 1988, 255:F1269-1275.
36. Menard J, Gonzalez M, Guyene T, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006, 24:1147-1155. 10.1097/01.hjh.0000226205.65442.f2, 16685215.
37. Ortiz RM, Graciano ML, Seth D, Awayda MS, Navar LG. Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. Am J Physiol Renal Physiol 2007, 293:F139-F147. 10.1152/ajprenal.00504.2006, 17376762.
38. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716. 10.1016/S0895-7061(02)02957-6, 12160194.
39. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008, 2:462-468. 10.1016/j.jash.2008.05.005, 20409927.
40. Aguilera G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. J Steroid Biochem Mol Biol 1993, 45:147-151. 10.1016/0960-0760(93)90134-I, 8481339.
41. Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC, Rainey WE. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 1997, 11:638-649. 10.1210/me.11.5.638, 9139807.
42. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart 1999, 82:57-61. 1729098, 10377310.
43. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 16:262-265.
44. Burton TJ, Cope G, Wang J, Sim JC, Azizan EAB, O'Shaughnessy KM, Brown MJ. Expression of the epithelial Na+ channel and other components of an aldosterone response pathway in human adrenocortical cells. Eur J Pharmacol 2009, 613:176-181. 10.1016/j.ejphar.2009.04.005, 19371736.